“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest Bing News on:
Cystic fibrosis
- R400k boost for cystic fibrosis fighterson May 9, 2024 at 4:10 pm
Breathtaking Fundraising, a non-profit that supports individuals with cystic fibrosis (CF) in South Africa, has received a R400,000 donation to address the significant challenge of medication ...
- Cystic Fibrosis focus of Clifford Craig Mother's Day fundraiseron May 9, 2024 at 11:01 am
The Launceston Friends of Clifford Craig celebrated their annual Mother's Day Luncheon fundraiser featuring an inspiring address from Cystic Fibrosis Tasmania vice president Judi McGee, who lost her ...
- Butte Calcutta raises more than $42,000 for Cystic Fibrosis supporton May 7, 2024 at 11:56 am
Organizers say the 10th annual Butte Cystic Fibrosis NCAA March Madness Calcutta was once again a success, raising $34,785 for the Cystic Fibrosis Foundation and another $8,500 for the Cody Dieruf ...
- Cystic Fibrosis Community Perspectives Influence Future of CF Care Modelon May 7, 2024 at 6:48 am
The Cystic Fibrosis Foundation conducted a national survey of people with cystic fibrosis, families, and clinicians to understand how CF care centers can adapt to meet the changing needs of people ...
- Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performanceon May 7, 2024 at 6:38 am
With a total revenue of nearly $2.7 billion, Vertex exceeded analyst estimates in the first quarter, bolstered by strong uptake of its cystic fibrosis products.
- Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trialon May 7, 2024 at 4:30 am
Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
- Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drugon May 6, 2024 at 1:22 pm
By Paul Ziobro Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter, topping Wall Street expectations, on continued growth of ...
- Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentson May 6, 2024 at 1:11 pm
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that ...
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Surveyon May 6, 2024 at 3:07 am
Parents of newborns often don’t understand early screening tests for disease like cystic fibrosis. Three out of four parents whose child had a positive newborn sc ...
- Survey of US parents highlights need for more awareness about newborn screening, cystic fibrosison May 5, 2024 at 12:00 pm
A national survey led by Ann & Robert H. Lurie Children's Hospital of Chicago found that parents have insufficient knowledge of newborn screening in general and of cystic fibrosis (CF) in particular.
The Latest Google Headlines on:
Cystic fibrosis
[google_news title=”” keyword=”Cystic fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cystic fibrosis treatment
- FTC Puts Pharmacy Benefit Managers, Private Equity in the Crosshairson May 10, 2024 at 7:59 am
In Part 2 of this exclusive video interview, MedPage Today editor-in-chief Jeremy Faust, MD, and Lina Khan, JD, chair of the Federal Trade Commission (FTC), discuss the agency's role in healthcare, ...
- R400k boost for cystic fibrosis fighterson May 9, 2024 at 4:10 pm
Breathtaking Fundraising, a non-profit that supports individuals with cystic fibrosis (CF) in South Africa, has received a R400,000 donation to address the significant challenge of medication ...
- Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSon May 9, 2024 at 5:59 am
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activitiesCash runway extended beyond ...
- Oregon State Researchers Develop Innovative Device to Enhance Gene Therapy Delivery for Lung Disease Treatmenton May 8, 2024 at 10:18 pm
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.In cell ...
- ‘We can complete that puzzle’: MU Health Care taps new diagnostic to improve lung disease treatmenton May 7, 2024 at 10:28 am
MU Health Care is just the second hospital in the U.S. to perform lung scans using xenon MRI, a groundbreaking technology that promises to greatly improve providers’ abilities to evaluate lung ...
- Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performanceon May 7, 2024 at 6:38 am
With a total revenue of nearly $2.7 billion, Vertex exceeded analyst estimates in the first quarter, bolstered by strong uptake of its cystic fibrosis products.
- Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trialon May 7, 2024 at 4:30 am
Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
- Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentson May 6, 2024 at 1:11 pm
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that ...
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Surveyon May 6, 2024 at 3:07 am
Parents of newborns diagnosed with cystic fibrosis often are confused about both the disease and their next steps, a new ...
- Chapel Hill drugmaker sees positive results for lung disease treatmenton May 1, 2024 at 12:16 pm
"These results show that Arina-1 can have a profound benefit for patients," CEO Dan Copeland said in a statement. "There are currently no approved therapies for bronchiectasis, and to see such a clear ...
The Latest Google Headlines on:
Cystic fibrosis treatment
[google_news title=”” keyword=”cystic fibrosis treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]